🇺🇸 FDA
Pipeline program

Blinatumomab

2024318

Approved small_molecule active

Quick answer

Blinatumomab for Acute B-cell Lymphoblastic Leukemia is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Acute B-cell Lymphoblastic Leukemia
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials